<DOC>
	<DOCNO>NCT02996916</DOCNO>
	<brief_summary>Hypertension lead risk factor morbidity mortality worldwide . The brain major target damage effect hypertension . Hypertension recognize lead cause dementia well important risk factor stroke vascular cognitive impairment . Although glucose principal cerebral energy source , impact hypertensive treatment cerebral glucose metabolism poorly understood .</brief_summary>
	<brief_title>Efficacy Olmesartan Cerebral Glucose Metabolism , Vascular Inflammation Adipose Tissue</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Written inform consent obtain Male female subject age 20 year old informed consent Essential hypertension never receive angiotensin II receptor antagonist calcium channel blocker Secondary hypertension malignant hypertension Diabetes mellitus History evidence stroke Hepatic hematologic abnormality Mild Cognitive Impairment Dementia Serum potassium level ≥ 5.5 mEq/L Serum creatinine level ≥ 3.0 mg/dL Acute chronic disease Allergy drug Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>